BNC 105

Drug Profile

BNC 105

Alternative Names: BNC 105P; BNC-105

Latest Information Update: 28 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Iliad Chemicals
  • Developer Bionomics
  • Class Anisoles; Antineoplastics; Benzofurans; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Tubulin polymerisation inhibitors; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Mesothelioma; Renal cell carcinoma
  • Phase I/II Ovarian cancer
  • Preclinical Colorectal cancer
  • No development reported Chronic lymphocytic leukaemia

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 28 May 2018 No recent reports of development identified for preclinical development in Chronic-lymphocytic-leukaemia in Australia
  • 05 Mar 2018 Dartmouth-Hitchcock Medical Center plans a phase I trial of BNC 105P (Combination therapy, Second-line therapy or greater) in Chronic lymphocytic leukaemia in March 2018 (NCT03454165)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top